Log in to search using one of your social media accounts:

 

Report: Olympus study of next-gen power morcellator draws criticism
Olympus (TYO:7733) is receiving criticism after moving forward with plans to revitalize its powered morcellator devices, with a new 140-patient trial planned, according to a Philadelphia Inquirer report. Power morcellators, which use a cutting tip to shred and remove uterine tissue, have been implicated in the spread of a lethal cancer that can masquerade undetected as benign fibroids. The devices designed to be used to remove benign uterine fibroids, but when used on malignant tissue, can spread cancerous cells throughout the abdomen. Olympus won FDA 510(k) clearance for a next-generation laparoscopic PK morcellator,...
Source: Mass Device - August 14, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Oncology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 13, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Vertos Medical raises $28m for Mild spine treatment Vertos Medical said yesterday that it closed a $28 million financing round for its Mild treatment for lumbar spinal stenosis. The round was led by new investor MVM Life Scienc...
Source: Mass Device - June 13, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Olympus settles power morcellator suit
An Olympus (TYO:7733) subsidiary agreed to settle a lawsuit filed over the power laparoscopic morcellator used in a gynecological surgery. Plaintiffs Betty and Elvis Dobson alleged that the Olympus KS PlasmaSORD used in Betty’s 2010 hysterectomy spread myxoid leiomyosarcoma cells in her abdomen and pelvis. Power morcellators use small, rotating blades to break up large tissue masses into fragments and are commonly used to remove benign uterine fibroids in women. Although the FDA approved morcellators in 1995, it wasn’t until 2013 that the late Dr. Amy Reed exposed the risk after undergoing a...
Source: Mass Device - June 13, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Legal News Women's Health Olympus Source Type: news

Four presentations of skin conditions
The presentation, diagnosis and management of cutaneous infection with Mycobacterium chelonae, basal cell carcinoma, leiomyosarcoma and disseminated superficial actinic porokeratosis. (Source: GP Online Education)
Source: GP Online Education - June 13, 2017 Category: Primary Care Tags: 15.10 Skin Problems Source Type: news

Patient safety pioneer Dr. Amy Reed dies at 44
The physician who helped put an end to the 18-year gap between the FDA’s approval of laparoscopic power morcellators and the safety watchdog learning that the devices can spread malignant cancers in the abdomen, Dr. Amy Reed, died yesterday of leiomyosarcoma, according to news reports. She was 44. Power morcellators use small, rotating blades to break up large tissue masses into fragments and are commonly used to remove benign uterine fibroids in women. But if the device is used on a patient with undetected cancer, it can strew cancerous cells throughout the abdomen. Although the FDA approved morcellat...
Source: Mass Device - May 25, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Women's Health Source Type: news

My hysterectomy and cancer journey – Anya ’ s story
The post My hysterectomy and cancer journey – Anya’s story appeared first on Hysterectomy Association. I had been suffering from heavy bleeding on and off since the birth of my second child in 2012 , medication and the contraceptive pill did nothing to ease the bleeding and I was referred to a gynaecologist, I initially saw a locum gynaecologist who persuaded me to have a Mirena coil fitted. However that made matters matters worse and some six months later following several appointments with another gynaecologist, a hysteroscopy and scans it was discovered that coil had managed to lodge itself in my uterus and ...
Source: The Hysterectomy Association - March 24, 2017 Category: OBGYN Authors: Linda Tags: Your Stories cancer leiomyosarcoma Source Type: news

PI3K/mTOR inhibitors may be effective against some uterine sarcomas
The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may respond to PI3K/mTOR inhibitors. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 23, 2017 Category: Science Source Type: news

PI3K/mTOR inhibitors may be effective against some uterine sarcomas
(American Association for Cancer Research) The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may respond to PI3K/mTOR inhibitors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2017 Category: Cancer & Oncology Source Type: news

Aldoxorubicin Improves PFS in Some Relapsed/Refractory Sarcomas
Aldoxorubicin yielded significantly better progression-free survival over investigator ’s choice of various chemotherapy options in patients with relapsed or refractory leiomyosarcoma and liposarcoma, according to updated results of a phase III trial. (Source: CancerNetwork)
Source: CancerNetwork - December 30, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news

Olympus wins FDA nod & launches new power morcellator with tissue capture
Olympus (TYO:7733) said today it won FDA 510(k) clearance for its next-gen laparoscopic PK morcellator with tissue containment designed as a laparoscopic surgery option to avoid open hysterectomy and myomectomy for uterine fibroid removal The company’s newly launched morcellator includes the company’s PneumoLiner contained tissue extraction system. “Contained tissue extraction is continually evolving. As surgeons, it is our duty to evaluate potential solutions to the surgical challenges we face in clinical practice. We are pleased that Olympus has taken the initiative to develop a unique and well tes...
Source: Mass Device - November 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Business/Financial News Food & Drug Administration (FDA) Regulatory/Compliance Women's Health Olympus Source Type: news

CURE Media Group Teams With National LeioMyoSarcoma Foundation and...
Partnership expands advocacy and empowerment for patients fighting cancer(PRWeb November 02, 2016)Read the full story at http://www.prweb.com/releases/CURE_MediaGroup/NLMSF_NCCS/prweb13816536.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 3, 2016 Category: Pharmaceuticals Source Type: news

Power morcellation rates plunged after FDA warnings
Use of electric power morcellation for hysterectomy procedures has significantly declined after the FDA warned against the use of such devices in 2014, according to a new study. Data from the study was published this month in the Journal of the American Medical Association. The study examined a total of 203,520 women who underwent hysterectomy procedures from 2013 to the 1st quarter of 2015 as recorded in the Perspective database, which includes more than 500 hospitals in the U.S. Researchers found that the use of power morcellators peaked in the 4th quarter of 2013 at 13.7%, and dropped to only 2.8% by the 1st quarter of ...
Source: Mass Device - August 23, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Women's Health Source Type: news

Avoid Morcellation When Malignancy Is SuspectedAvoid Morcellation When Malignancy Is Suspected
Dr Peter Kovacs summarizes a new study that found that morcellation is associated with decreased early survival in women with occult leiomyosarcomas. Medscape Ob/Gyn (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2016 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Viewpoint Source Type: news

Johnson & Johnson looks to settle morcellator lawsuits
Johnson & Johnson(NYSE:JNJ) is reportedly looking to settle 100s of product liability and wrongful death lawsuits brought over its now-recalled laparoscopic power morcellators used during surgeries to remove ostensibly benign uterine tumors. The morcellators, which use a cutting tip to shred and remove uterine tissue, have been implicated in the spread of a lethal cancer that can masquerade undetected as benign fibroids. The FDA in April 2014 issued a warning about the devices, later convening a special advisory panel to evaluate their continued use in the surgical suite. The watchdog agency estimat...
Source: Mass Device - March 21, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Legal News Product Liability Surgical Ethicon Inc. Johnson & Johnson Source Type: news

Learn About Each Type of Colon Cancer
Adenocarcinoma is the most common type of colon cancer but there are many other forms as well. Examples include leiomyosarcoma, lymphoma, melanoma, and neuroendocrine tumors. Here, you can learn more about each type of colon cancer. (Source: About.com Colon Cancer)
Source: About.com Colon Cancer - March 1, 2016 Category: Cancer & Oncology Authors: coloncancer.guide at about.com Tags: health Source Type: news

Just what is Leiomyosarcoma?
Leiomyosarcomas account for less than two percent of colorectal cancers and have a fairly high chance of spreading. Learn more about leiomyosarcomas. (Source: About.com Colon Cancer)
Source: About.com Colon Cancer - February 26, 2016 Category: Cancer & Oncology Authors: coloncancer.guide at about.com Tags: health Source Type: news

Primary Leiomyosarcoma of the Submandibular GlandPrimary Leiomyosarcoma of the Submandibular Gland
Leiomyosarcoma is a rare malignant mesenchymal tumor; and even rarer in the salivary gland. How was diagnosis ascertained in this case? BMC Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 29, 2016 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Janssen's Yondelis gets FDA approval to treat unresectable or metastatic LPS or LMS
Janssen Biotech has received approval from the US Food and Drug Administration (FDA) for Yondelis (trabectedin) to treat patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 26, 2015 Category: Pharmaceuticals Source Type: news

FDA approves new therapy for certain types of advanced soft tissue sarcoma
The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who previously received chemotherapy that contained anthracycline. (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 23, 2015 Category: American Health Source Type: news

World's First Partial Skull And Scalp Transplant A Success In Texas
Opening a new frontier in transplant surgery, Texas doctors have done the world's first partial skull and scalp transplant to help a man who suffered a large head wound from cancer treatment. Doctors from Houston Methodist Hospital and MD Anderson Cancer Center did the operation two weeks ago. The recipient — Jim Boysen, a 55-year-old software developer from Austin, Texas — expects to leave the hospital Thursday with a new kidney and pancreas along with the scalp and skull grafts. He said he was stunned at how well doctors matched him to a donor with similar skin and hair coloring. "It's kind of shockin...
Source: Science - The Huffington Post - June 5, 2015 Category: Science Source Type: news

World's First Skull-Cap Transplant Helps Jim Boysen Fight Cancer
Opening a new frontier in transplant surgery, Texas doctors have done the world's first partial skull and scalp transplant to help a man who suffered a large head wound from cancer treatment. Doctors from Houston Methodist Hospital and MD Anderson Cancer Center did the operation two weeks ago. The recipient - Jim Boysen, a 55-year-old software developer from Austin, Texas - expects to leave the hospital Thursday with a new kidney and pancreas along with the scalp and skull grafts. He said he was stunned at how well doctors matched him to a donor with similar skin and hair coloring. "It's kind of shocking, really, h...
Source: Science - The Huffington Post - June 5, 2015 Category: Science Source Type: news

Fibroid Morcellation Gets Boost From New Study (CME/CE)
(MedPage Today) -- But procedure was linked to more leiomyosarcoma deaths. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 25, 2015 Category: Primary Care Source Type: news

Leiomyosarcoma of the Colon and Rectum
Colorectal sarcomas occur in the smooth muscle of the colon and are called leiomyosarcomas. Leiomyosarcomas account for less than two percent of colorectal cancers and have a fairly high chance of spreading. (Source: About.com Colon Cancer)
Source: About.com Colon Cancer - February 22, 2015 Category: Cancer & Oncology Authors: coloncancer.guide at about.com Tags: health Source Type: news

Power Morcellator Cancer Risk Confirmed by FDA, As Bernstein Liebhard...
The FDA's new morcelltor cancer warning comes amid growing concerns that uterine morcellation may have caused numerous women to experience the spread of uterine sarcoma, leiomyosarcoma and other...(PRWeb November 25, 2014)Read the full story at http://www.prweb.com/releases/morcellator-lawsuit/morcellator-cancer/prweb12355345.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 26, 2014 Category: Pharmaceuticals Source Type: news

PharmaMar announces US partner Janssen files NDA for YONDELIS for soft-tissue sarcoma
(Pharmamar) Based on a phase 3 trial in which dacarbazine was used in the comparator arm, Janssen has submitted a NDA for YONDELIS (trabectedin) to the FDA for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma, who have received prior chemotherapy including an anthracycline. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2014 Category: Cancer & Oncology Source Type: news

Uterine Leiomyosarcoma: Rare Tumor in Clinical TrialsUterine Leiomyosarcoma: Rare Tumor in Clinical Trials
Dr Martee Hensley discusses the difficulty in differentiating benign uterine fibroids from malignancy, the controversy over morcellation, and initiatives undertaken to manage uterine leiomyosarcoma. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 19, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Expert Interview Source Type: news

Power Morcellator News: Bernstein Liebhard LLP Notes Uncle’s Plea to...
The Firm is evaluating potential morcellator lawsuits on behalf of woman who allegedly experienced the spread of gynecological cancers, including uterine sarcoma and leiomyosarcoma, following uterine...(PRWeb November 17, 2014)Read the full story at http://www.prweb.com/releases/morcellator-lawsuit/morcellator-cancer/prweb12332279.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 18, 2014 Category: Pharmaceuticals Source Type: news

Mycosis Fungoides and Leiomyosarcoma – Cancer Therapeutic Drugs and...
RnRMarketResearch.com adds “Mycosis Fungoides and Leiomyosarcoma – Pipeline Review, H2 2014” to its store. The report provides an overview of the Mycosis Fungoides and Leiomyosarcoma therapeutic...(PRWeb October 31, 2014)Read the full story at http://www.prweb.com/releases/2014-h2-retinoblastoma/leiomyosarcoma-pipeline/prweb12293087.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 1, 2014 Category: Pharmaceuticals Source Type: news

Minimally Invasive Uterine and Fibroid Morcellation Warnings
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. In recent months there have been a number of warnings issued about uterine polyp and fibroid morcellation during laparascopic hysterectomy or myomectomy, most notably by the FDA in the United States. It’s come about because in a small number of cases the fibroids being removed were shown to be malignant after the surgery, something that was not known prior to the operation. In a few of these cases women went on to develop leio...
Source: The Hysterectomy Association - September 22, 2014 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Alternatives to Hysterectomy laparascopic hysterectomy morcellation myomectomy Source Type: news

Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of...
The Firm is evaluating morcellator lawsuits on behalf of women who experienced the spread of uterine sarcoma, leiomyosarcoma and other uterine cancers, allegedly due to uterine morcellation.(PRWeb August 27, 2014)Read the full story at http://www.prweb.com/releases/power-morcellator-lawsuit/uterine-sarcoma-cancer/prweb12125752.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 28, 2014 Category: Pharmaceuticals Source Type: news

Morcellation Lawsuist Filed by Alonso Krangle LLP Alleges Woman Was...
A Morcellator Lawsuit Has Been Filed on Behalf of a New York Woman Who Was Diagnosed with Uterine Leiomyosarcoma Cancer after Undergoing a Robot-Assisted Hysterectomy with Uterine Morcellation(PRWeb May 02, 2014)Read the full story at http://www.prweb.com/releases/2014/05/prweb11820274.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 3, 2014 Category: Pharmaceuticals Source Type: news

Morcellation Lawsuit Scrutinizes Procedure; FDA Calls For End to...
In Wake of Morcellation Lawsuit FDA Calls For Termination of Procedures Using Laparoscopic Power Morcellation That Allegedgly Causes Leiomyosarcoma, reports Alonso Krangle LLP(PRWeb April 18, 2014)Read the full story at http://www.prweb.com/releases/2014/04/prweb11777448.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 18, 2014 Category: Pharmaceuticals Source Type: news

Primary Venous Leiomyosarcoma: Imaging ModalitiesPrimary Venous Leiomyosarcoma: Imaging Modalities
Learn how cross-sectional imaging can help distinguish rare intravenous leiomyosarcomas from other intravascular and retroperitoneal tumors in this case study. Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2014 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Types of Colon Cancer - Learn about Each Type...
Adenocarcinoma is the most common type of colon cancer but there are many other forms as well. Examples include leiomyosarcoma, lymphoma, melanoma, and neuroendocrine tumors. Here, you can learn more about each type of colon cancer. (Source: About.com Colon Cancer)
Source: About.com Colon Cancer - July 11, 2013 Category: Cancer & Oncology Authors: coloncancer.guide at about.com Tags: health Source Type: news